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Introduction: Regulatory T (Treg) cells play a crucial role in preventing autoimmune diseases and are an ideal
target for the development of therapies designed to suppress inflammation in an antigen-specific manner.
Type 1 regulatory T (Tr1) cells are defined by their capacity to produce high levels of interleukin 10 (IL-10), which
contributes to their ability to suppress pathological immune responses in several settings. The aim of this study was
to evaluate the therapeutic potential of collagen type II–specific Tr1 (Col-Treg) cells in two models of rheumatoid
arthritis (RA) in mice.
Methods: Col-Treg clones were isolated and expanded from collagen-specific TCR transgenic mice. Their cytokine
secretion profile and phenotype characterization were studied. The therapeutic potential of Col-Treg cells was
evaluated after adoptive transfer in collagen-antibody– and collagen-induced arthritis models. The in vivo
suppressive mechanism of Col-Treg clones on effector T-cell proliferation was also investigated.
Results: Col-Treg clones are characterized by their specific cytokine profile (IL-10highIL-4negIFN-γint) and mediate
contact-independent immune suppression. They also share with natural Tregs high expression of GITR, CD39 and
granzyme B. A single infusion of Col-Treg cells reduced the incidence and clinical symptoms of arthritis in both
preventive and curative settings, with a significant impact on collagen type II antibodies. Importantly, injection of
antigen-specific Tr1 cells decreased the proliferation of antigen-specific effector T cells in vivo significantly.
Conclusions: Our results demonstrate the therapeutic potential of Col-Treg cells in two models of RA, providing
evidence that Col-Treg could be an efficient cell-based therapy for RA patients whose disease is refractory to current
treatments.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by synovial inflammation and destruc-
tion of joint cartilage and bone and mediated by persistent
synthesis of proinflammatory cytokines and matrix metal-
loproteinases. Proinflammatory cytokines such as inter-
leukin 6 (IL-6), tumor necrosis factor α (TNF-α) and
IL-1β are critical mediators in the inflammatory process
of arthritis [1,2]. In the past several years, biologic drugs* Correspondence: pascale.plence@inserm.fr
†Equal contributors
2Inserm, U844, University of Montpellier 1, 80 rue Augustin Fliche, 34295
Montpellier, Cedex 05, France
Full list of author information is available at the end of the article
© 2014 Asnagli et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.have been developed to antagonize the effector cytokines,
and neutralizing TNF-α or IL-6 has been proven to be
successful in the treatment of RA. Despite the clinical
benefit of such biologics aimed at ensuring broad im-
munosuppression, a nonnegligible proportion of patients
eventually escape. For example, treatment failures can be
related to the development of an immune response against
the biologic itself, thus leading to loss of efficacy over time
[3-5]. As a consequence of these failures, there is still a
need for new therapies with the aim of proactively resto-
ring immune balance and reestablishing tolerance to joint
antigens while avoiding systemic immune suppression.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Asnagli et al. Arthritis Research & Therapy 2014, 16:R115 Page 2 of 12
http://arthritis-research.com/content/16/3/R115Regulatory T (Treg) cells have been shown to play a cru-
cial role in inhibiting autoimmune diseases and could be a
valuable, interesting tool for use in therapeutic interven-
tions, including in RA treatment. Indeed, Treg cells are
ideal for this purpose because they suppress inflammation
in an antigen-specific manner and can achieve selective
and durable inhibition of pathologic inflammation without
blocking protective immune responses against infection.
The results of many animal model studies [6-10], as well
as clinical studies, have indicated a link between the effi-
cacy of therapies against arthritis and the increase in the
number or function of Treg cell populations [11-14]. In
addition, oral tolerization protocols developed several
years ago have shown disease reduction in RA murine
models and have recently been associated with the de-
velopment of a population of Treg cells that suppress
inflammation via IL-10 production [15,16]. More impor-
tantly, treatment of RA patients with anti-TNF antibodies
has been shown to induce differentiation of a potent
population of Treg cells with suppressive activity that is
dependent upon transforming growth factor β (TGF-β)
and IL-10 [12,13].
Because of the heterogeneity of human Treg cells,
there is no consensus to date about which Treg cell
population is optimally suitable for clinical use. Investi-
gators in several phase I clinical trials have tested the
ability of ex vivo–expanded CD4+CD25+ Treg cells to
prevent graft versus host disease after allogeneic bone
marrow transplantation [17-19]. The use of such Treg
cell populations has been hampered by the low number
of circulating Tregs in humans and by the need to ex-
pand large amounts of suppressive cells for clinical use.
Based on the therapeutic potential of type 1 regulatory T
(Tr1) cells in inflammatory bowel disease (IBD) models
[20] and on the possibility of generating large numbers
of antigen-specific Tr1 cells in vitro [21,22], a phase I/II
clinical trial in which the researchers used ovalbumin-
specific type 1 regulatory T (ova-Treg) cells has been
performed in severe Crohn’s disease patients with pro-
duction of very promising clinical data and indications
of safety and efficacy [23]. These results and the possi-
bility of isolating and expanding functional collagen type
II–specific type 1 regulatory T (Col-Treg) cell clones
from RA patients [22], suggesting that Tr1 cell–based
therapy could be a novel therapeutic strategy for treating
patients with RA.
Tr1 cells are characterized by the secretion of high
amounts of IL-10. Adoptive transfer of antigen-specific
Tr1 cells has been shown to be efficacious in suppressing
inflammation in a variety of animal models for chronic in-
flammatory and autoimmune diseases, such as colitis, type
1 diabetes, multiple sclerosis, allergy and transplantation
[20,24-28]. In these settings, the putative mechanism of
action of antigen-specific Tr1 cells can be summarized inthree steps: (1) homing to the site of inflammation, (2)
local recognition of the specific antigen presented by local
antigen-presenting cells and (3) local suppression of
inflammation mediated by soluble factors and immuno-
modulatory surface molecules. By their mode of action,
Tr1 cells are able to deliver local immunosuppression to
the inflamed tissue.
Our goal in the present study was to evaluate the
therapeutic potential of Col-Treg cells in experimental
models of arthritis in order to propose their use in a
new cell-based immunotherapy in joint inflammatory




All experiments were performed in accordance with na-
tional guidelines and approved by the local ethics com-
mittee (Committee on the Ethics of Animal Experiments in
Languedoc-Roussillon (CEEA-LR-1067)) and the French
National Authority for Health (A06-152-10 and B34-172-
36).
Mice
BALB/c and DBA/1 mice were obtained from Harlan
Laboratories (Indianapolis, IN, USA). DO11.10 and
CD90.2 congenic BALB/c mice were kindly provided by
H Yssel and J Hernandez, respectively, and mice were
bred in our own animal facility. Transgenic mice car-
rying the rearranged Vα11.1 and Vβ 8.2 T-cell receptor
(TCR) chain genes isolated from a collagen type II (Col
II)–specific T-cell hybridoma were kindly provided by
REM Toes (Leiden University Medical Center, Leiden,
the Netherlands) with approval from W Ladiges [29].
Generation of collagen-specific and ovalbumin-specific
type 1 regulatory T cells
Col-Treg clones were generated from Col II–specific
transgenic mice. Briefly, splenocytes were stimulated in
the presence of bovine Col II (0.5 μg/ml) (MD Biosciences,
Zurich, Switzerland), recombinant human (rhu) IL-10
(50 ng/ml) (R&D Systems, Minneapolis, MN, USA) and
anti-IL-4 antibodies (10 μg/ml) (clone 11B11; eBioscience,
San Diego, CA, USA). Similarly, ova-Treg clones were
generated as previously described [26] from DO11.10
transgenic mice, stimulated in the presence of 0.3 μM
OVA323–339 peptide (Bachem, Bubendorf, Switzerland). In
both cases, recombinant murine IL-10 (5 ng/ml; R&D
Systems) was added on day 2, and cells were cloned by
limiting dilution in the presence of coated anti-CD3
monoclonal antibodies (mAbs) (5 μg/ml) (clone 145.2C11;
BD Biosciences, San Jose, CA, USA) in the presence of
irradiated syngeneic splenocytes. T-cell clones were then
expanded in the presence of rhu IL-2 (aldesleukin;
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(5 μg/ml) and soluble anti-CD28 (1 μg/ml) mAbs. T cells
were further expanded in the presence of anti-CD3/
anti-CD28 mAb–coated beads (Invitrogen, Carlsbad, CA,
SUA) with addition of IL-2 on day 2, with an average 240-
fold expansion over the course of 2 weeks.
Characterization of collagen-specific regulatory T cells
Cytokines in the culture supernatants were quantified by
enzyme-linked immunosorbent assay (ELISA) with IL-4
and IL-10 (BD Biosciences) and interferon γ (IFN-γ)
(R&D Systems) following 48 hours of polyclonal stimula-
tion (coated anti-CD3 and soluble anti-CD28 mAbs) of
Treg cells in expansion (no IL-10 added). Intracellular
cytokine secretion staining of CD4+Vβ8.2+ clones was
analyzed by fluorescence-activated cell sorting (FACS)
using fluorescent dye–conjugated anti-IL-10, anti-IFN-γ,
anti-IL-4, anti-IL-13 and anti-IL-17 mAbs (eBiosciences
or BD Biosciences) after 4 hours of stimulation with
phorbol 12-myristate 13-acetate (50 ng/ml) and ionomy-
cin (1 μg/ml) in the presence of brefeldin A (10 μg/ml).
Selected Col-Treg clones were further characterized by
FACS analysis using fluorescent dye–conjugated mAbs spe-
cific for CD25, FoxP3, CD127, CD62L (BD Biosciences)
and glucocorticoid-induced tumor necrosis factor family re-
ceptor (GITR), cytotoxic T lymphocyte-associated antigen
4 (CTLA-4), granzyme B, CD39 and CD73 (eBiosciences).
Cells were stained according to standard procedures.
Data were acquired on a FACSAria flow cytometer (BD
Biosciences), and the results were analyzed with FACS-
Diva software (BD Biosciences).
The immunosuppressive function of Col-Treg clones
was evaluated by cell contact–independent in vitro assay
in transwell plates using a method adapted from that
described by Battaglia et al. [30]. Briefly, we used as
responder cells freshly isolated splenocytes stained with
carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Invitrogen) and plated them in the presence of anti-CD3
mAbs (5 μg/ml) in the bottom well of a 96-transwell plate
(0.8 × 106 cells/well). We added either medium alone or
selected Col-Treg clones (0.05 × 106 cells/well) activated
with anti-CD3/anti-CD28-coated beads in the upper well.
After 3 days, the proliferation of responder cells was eva-
luated by FACS analysis of CFSE dilution staining on CD4+
cells. The suppressive capacity of clones was measured by
comparing the percentage of CFSE+ divided cells obtained
in the presence of Col-Treg clones with the percentage of
CFSE+ divided cells obtained without any added cells.
Induction and clinical evaluation of collagen
antibody–induced arthritis
We delivered a cocktail consisting of 5 or 6 mg of
arthritogenic antibodies specific for Col II epitopes (MD
Biosciences) by intraperitoneal injection into male 9-week-old DBA/1 mice. On day 3 after the cocktail injection, we
intraperitoneally injected into the mice 100 μg of lipopoly-
saccharide (LPS) (MD Biosciences), and, a few hours later,
we injected Col-Treg cells by intravenous retro-orbital de-
livery into the venous sinus. Starting from day 3 after the
initial injection, disease severity was scored daily based on
clinical scores according to the following scale: 0 = normal,
1 = weak swelling, 2 = significant swelling associated with
redness, 3 = intermediate swelling associated, or not, with
redness and 4 =maximal swelling and/or redness in all in-
flamed digits. A total score of 20 was recorded for each
mouse and added to a total score of 2 based on the
number of inflamed digits [31]: 0 = no inflamed digits,
0.5 = zero to five inflamed digits, 1 = six to ten inflamed
digits, 1.5 = one to fifteen inflamed digits and 2 = 16 or
more inflamed digits. In addition to the clinical score, the
mice were analyzed for body weight loss.
Collagen-induced arthritis induction and evaluation
We immunized male 9- to 12-week-old DBA/1 mice at
the base of the tail with 100 μg of bovine Col II (MD
Biosciences) emulsified in complete Freund’s adjuvant.
On day 21 after arthritis induction, we delivered a
booster immunization at the base of the tail with 100 μg
of bovine Col II emulsified in incomplete Freund’s ad-
juvant (IFA). We injected Col-Treg cells (intravenous
retro-orbital injection) into the mice on day 20, 22 or 28
after arthritis induction. From day 21 onward, the thick-
ness of each hind paw was measured with a caliper three
times per week, and the severity of arthritis was graded
using the same clinical scale described for collagen
antibody–induced arthritis (CAIA). The score data are
expressed as means ± SEM on a given day.
Histopathology
At experimental endpoints, joints were collected, fixed in
10% neutral buffered formalin, decalcified in 5% ethylene-
diaminetetraacetic acid–based decalcification solution for
several days and embedded in paraffin, and sections were
stained with hematoxylin and eosin. Each joint (ankle and
wrist) was scored in a blinded manner by two independent
histopathologists (MD Biosciences). Infiltration was scored
as follows: 0 = no change, 1 =modest leukocyte infiltration
into synovial tissue with no fluid leukocytes, 2 =modest
leukocyte infiltration into synovial tissue in fluid phase with
no loss of synovial architecture and 3 = gross leukocyte in-
filtration into synovial membrane and fluid space with sig-
nificant loss of synovial and articular architecture. Erosion
was scored as follows: 0 = no abnormality, 1 = fibrillation of
cartilage and/or mild erosive infiltration of periosteal and
subchondral bone, 2 =moderate fibrillation and loss of
cartilage and/or erosive infiltration of periosteal and sub-
chondral bone and 3 = significant loss of cartilage and/or
erosive infiltration of periosteal and subchondral bone.
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Serum levels of immunoglobulin G1 (IgG1), IgG2a and
total IgG antibodies against bovine Col II were measured
by standard ELISA using pooled sera from arthritic mice
as a reference standard and assigned an arbitrary level of
antigen-specific antibodies [32].Detection of collagen-specific regulatory T cells by
quantitative PCR
For the detection of Col-Treg cells by PCR, primers
and dual-label probe (6-carboxyfluorescein and Toll/IL-1
receptor domain–containing adapter inducing IFN-β, or
FAM-TRAM; Sigma-Aldrich, St Louis, MO, USA) were
designed for the specific TCR VDJ (variable, diversity,
joining) recombination genetic sequence expressed by
transgenic mice [29]. Quantitative PCRs were performed
on total tissue-derived genomic DNA extracted using
the GenElute Mammalian Genomic DNA Miniprep Kit
(Sigma-Aldrich). The data derived from real-time quan-
titative PCR (DNA Engine Opticon 2 System; Bio-Rad
Laboratories, Hercules, CA, USA) were expressed as the
number of transgenic positive cells (determined based on
standard curves using dilution of transgenic cells in
nontransgenic cells) per miligrams of tissue or per organ,
for lymph nodes (LNs) and eyes.Ovalbumin-specific delayed-type hypersensitivity
We injected CFSE-labeled, ova-specific CD4 cells (3 to 4 ×
106 cells isolated from DO11.10 mice) into male 9-week-
old BALB/c mice. On the day afterward (day 0), these mice
were immunized by subcutaneous injection at the tail base
with ova (100 μg) emulsified in IFA. On day 5, injection of
ovalbumin/phosphate-buffered saline (ova-PBS) (30 μg)
was performed in one hind paw, and PBS was injected into
the other contralateral paw. On the same day, 1 × 106 ova-
specific Treg cells were injected intravenously and the mice
were killed 48 hours later. Draining lymph nodes (DLNs)
were recovered and counted, and 2 × 106 cells were stained
with CD4 and KJ1.26 mAbs to determine the percentage
of KJ1.26+ effector cells in the DLNs and the dilution of
CFSE staining. For the homing experiment, the same
procedures were carried out using CD90.1 BALB/c
congenic mice and injecting a higher dose of ova-Treg cells
(10 × 106) were injected. The CD90.2 congenic marker was
used to track the injected Treg cells by FACS.Statistical methods
Statistical analyses were performed by nonparametric
Mann–Whitney U test with InStat software (GraphPad
Software, La Jolla, CA, USA). A P-value <0.05 was con-
sidered statistically significant.Results
Collagen II–specific type 1 regulatory T cell clone
characterization
Col-Treg clones were expanded in vitro from Col II–spe-
cific TCR transgenic mice in the presence of IL-10 as pre-
viously described for antigen-specific Tr1 clones in both
mice and humans [20,21,26]. After expansion, clones were
selected based on Col II–specific TCR Vβ8 and CD4
expression (Figure 1A) as well as on their cytokine secre-
tion profile: IL-10highIL-4negIFN-γint (Figure 1B and C).
Additional characterization showed that selected Col-
Tregs coproduce IL-13 together with IL-10, but do not ex-
press IL-17 (Figure 1B), as recently described for human
ova-Treg cells [23]. The selected Col-Treg clones were
further characterized based on their immunosuppressive
activity in a cell-contact–independent in vitro assay. In
contrast to control type 1 T helper (Th1) cells, Col-Treg
clones were able to significantly inhibit proliferation of
anti-CD3 activated CD4+ T cells (Figure 1D). Quantitation
of their suppressive capacity showed 30% to 40% in-
hibition of the proliferation of CD4+ effector T cells
(Figure 1D) concomitantly with reduction of IFN-γ levels
produced by CD4+ T cells (data not shown).
As previously shown for Tr1 cells [21,22,28,33], and in
contrast to thymus-derived CD4+CD25+ Tregs, Col-Treg
clones do not constitutively express high levels of FoxP3
and CD25 (data not shown). In addition, upon activation,
Col-Treg cells display a phenotype of induced Treg (iTreg)
cells with low expression levels of CD127 and CD62L and
induction of several activation markers, including GITR,
granzyme B, CTLA-4 and CD39 (Figure 1F). The expres-
sion of such markers has been described previously for
natural Treg (nTreg) cells and iTreg cells [34-36], as well
as for Tr1 cells [21,28].
Collagen type II–specific type 1 regulatory T cell clones
inhibit acute arthritis
To evaluate the therapeutic potential of Col-Treg cells in
arthritis, Col-Treg clones were first tested in a model of
model acute arthritis induced by the administration of
arthritogenic antibodies (CAIA) (reviewed in [37]). Col-
Tregs (1 × 106 cells per animal at day 3) were injected
once before the administration of LPS and disease onset.
In this semipreventative treatment regimen, Col-Treg cells
were able to significantly reduce paw swelling, arthritis
severity and body weight loss (Figure 2). Although all mice
treated with Col-Treg cells developed arthritis by the end
of the experiment, we observed a slight but significant
delay, compared with control mice, of paw swelling in as-
sociation with disease progression (Figure 2B). Migration
of the injected Col-Treg cells was evaluated in this model
of acute arthritis. Twenty-four hours after the injection,
cells were distributed in highly vascularized tissues, such
as lung and liver, as well as in several peripheral DLNs
Figure 1 Phenotypic characterization of the collagen type II–specific type 1 regulatory T cell clones. (A) Graphed data of representative
fluorescence-activated cell-sorting (FACS) analysis of the selected clones for the expression of T-cell receptor Vβ8 and CD4. (B) Graph illustrating
the results of representative FACS analysis of intracellular cytokine staining of collagen type II–specific type 1 regulatory T cell (Col-Treg) clones
following 4 hours of polyclonal stimulation. IFN, Interferon; IL, Interleukin. (C) Graph showing the cytokine secretion profile of three representative
Col-Treg clones. The cytokine levels were quantified by enzyme-linked immunosorbent assay in the culture supernatants after 48 hours of polyclonal
stimulation. The data are expressed as mean ± SEM. (D) Graph describing the immunosuppressive activity of Col-Treg clones, measured in a cell
contact–independent assay by carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution, after 3 days of coculture with freshly isolated splenocytes
stimulated with anti-CD3 antibody. The data are representative of at least seven clones. Th1, Type 1 T helper cell. (E) Graph of the expression levels of
several phenotypic markers following 24 hours of polyclonal stimulation. Values are mean ± SEM of the percentage of positive cells for each marker.
The data are representative of three to eighteen clones.
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sinus injection, a high number of cells were still present in
the eyes (Figure 2D).
Collagen type II–specific type 1 regulatory T cell clones
inhibit chronic arthritis
As RA develops as a chronic disease, we tested Col-Treg
clones in the CIA model, which mimics the human
pathology involving both T- and B-cell responses [38].
Col-Treg clones were first injected as a semipreventative
treatment either before (day 20) or after (day 22) the re-
call of the immunization. In these experiments, Col-Treg
clones (1 × 106 cells per animal) reduced disease severity
as shown by a decrease in arthritis score and prevented
body weight loss. In addition, 3 weeks after treatment,though 100% of the animals in the control group deve-
loped arthritis, only 60% to 70% of the mice in the Treg-
treated group developed the disease (data not shown).
To assess whether we could improve the clinical benefit
of treatment by increasing the number of Col-Treg cells,
we injected either 1 × 106 or 3 × 106 Col-Treg cells into
the mice on day 20. The severity and incidence of arthritis
(Figures 3A and 3B), as well as body weight loss (data not
shown), were significantly reduced in the Treg-treated
group. Interestingly, a significant reduction of Col II–
specific antibody titers, in particular a reduction of the
Th1-associated IgG2a isotype antibody level, was observed
following injection of 3 × 106 Col-Tregs (Figure 3C). We
observed that the clinical response was associated with a
reduction in histology scores, particularly a significant
Figure 2 Single administration of collagen type II–specific type 1 regulatory T cell cells reduces acute collagen-antibody-induced
arthritis. We administered intraperitoneal injections of lipopolysaccharide (100 μg) into DBA/1 mice at day 3 after arthritis induction, followed 2 to
4 hours later by intravenous injections of 1 × 106 collagen type II–specific type 1 regulatory T cell (Col-Treg) clones (open triangles; n= 6) or saline buffer
solution (closed circles; n = 6). Mice not injected with antibody were used as controls (X’s; n = 2). After T-cell infusion, the mice were evaluated daily for
clinical signs of arthritis. (A) Graphed mean ± SEM data of the severity scores of arthritic mice are shown. Differences were analyzed by nonparametric
Mann–Whitney U test. The data are representative of two independent experiments. *P< 0.05 with 95% confidence interval for comparison of arthritic
and saline-injected control mice. (B) Disease incidence represents the percentage of arthritic mice at each time point. (C) Percentages of body weight
loss are shown. (D) Graph illustrating the trafficking of type 1 regulatory T cell clones analyzed 24 hours after intravenous infusion of 1 × 106 cells in
collagen antibody–induced arthritis mice (n = 6). The data are expressed as mean ± SEM of the number of transgenic positive cells detected in various
organs, including joint tissues, determined by quantitative PCR using standard curves. LN, Lymph node. mLN, Mesentheric LN. Ing. LN, Inguinal LN. Pop.
LN, Popliteal LN. Ax. LN, Axillary LN.
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This small difference could be explained by the fact that at
the time the mice were killed, 80% of Treg-treated mice
had arthritis. We also monitored the distribution of Col-
Treg clones in the CIA model. As we observed in the
CAIA acute arthritis model, Col-Treg cells in CIA mice
migrated in highly vascularized organs, such as lung, liver
and kidneys, and within joints and several LNs (Figure 3F).
In addition, within 24 hours postinfusion, Col-Treg cells
were detected in the spleens of CIA mice, whereas they
were undetectable in CAIA mice. We performed similar
analyses at 2 and 4 months after Treg injection and found
that only one of seventeen mice showed a positive signal
in one axillary LN, suggesting absence of uncontrolled
proliferation of Col-Treg cells, even in the presence of
both antigens and inflammation (data not shown).
Clinical benefit of collagen type II–specific type 1 regulatory
T cell treatment at disease onset
In order to further assess their therapeutic potential, we
injected Col-Treg cells later in the disease course, at day 28,
early in disease onset. As observed for semipreventativetreatment (Figure 3), both 3 × 106 and 1 × 106 Col-Treg cell
doses delayed arthritis onset and decreased its incidence
(Figure 4B). More importantly, we observed a significant
decrease in arthritis severity from day 44 following injection
of 1 × 106 cells (Figure 4A). The therapeutic effect was asso-
ciated with a significant decrease in anti-Col II–IgG anti-
bodies for both tested doses (Figure 4C). No preferential
decrease in the Th1-associated IgG2a isotype was observed
following injection at day 28, in contrast to the results ob-
served after injection at day 20 (Figure 3), suggesting that
an injection of Treg cells at the onset of clinical scoring did
not impact the Th1–Th2 cell balance. Altogether, these re-
sults underscore the therapeutic potential of Col-Treg cells
for clinical application and the need to clearly define the
optimal dose of cells and the optimal timing of Treg cell–
based therapy in a defined experimental model.
Antigen-specific type 1 regulatory T cells migrate to draining
lymph nodes and dampen proliferation of effector T cells
We further investigated the in vivo suppressive me-
chanism of Tr1 cells, and notably their impact on the
proliferation of effector T cells, using an ova-specific,
Figure 3 Decrease of inflammation, bone erosion and B-cell response following injection of collagen type II–specific type 1 regulatory
T cells at day 20 in murine collagen-induced arthritis. In the DBA/1 mice, we administered intravenous injections of collagen type II–specific
type 1 regulatory T cell (Col-Treg) clones in quantities of 1 × 106 (open triangles; n = 9) or 3 × 106 (closed triangles; n = 9) or saline buffer solution
(closed circles; n = 9) at day 20 postimmunization. After the T-cell infusions, the mice were clinically monitored every other day. (A) Graphed mean ±
SEM data of the arthritis severity scores are shown. Differences were analyzed by nonparametric Mann–Whitney U test (*P < 0.05 with 95% confidence
interval represent statistically significant differences between the arthritic and saline-injected mice). (B) The disease incidence in each group of mice is
shown. (C) Bovine collagen II–specific total immunoglobulin G (IgG), IgG1 and IgG2a levels in sera collected at the time mice were killed. Values
expressed in arbitrary units are mean ± SEM. Asterisk represents a significant difference between arthritic and saline-injected mice. (D) At the time mice
were killed, tissue sections were taken from the hind paws and forepaws for histological staining and scored for erosion, infiltration and hyperplasia.
The values shown are mean ± SEM of each paw from nine mice per group. (E) Representative images of histological sections of hind paws stained with
hematoxylin and eosin in control mice (left panel) or Col-Treg–treated mice (right panel). Arrows indicate hyperplasia, inflammation or erosion. Original
magnification of both images = 40×. (F) Trafficking of type 1 Treg clones was analyzed 24 hours after intravenous retro-orbital infusion of 3 × 106 Treg
cells in various organs, including joint tissues (n= 9). LN, Lymph node. Nb, Number. mLN, Mesentheric LN. Ing. LN, Inguinal LN. Pop. LN, Popliteal LN. Ax.
LN, Axillary LN.
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Figure 4 Collagen type II–specific type 1 regulatory T cells reduce the severity of ongoing collagen-induced arthritis. At day 28 after
induction of arthritis, bovine collagen II–immunized DBA/1 mice received injections of either 1 or 3 × 106 collagen type II–specific type 1 regulatory
T (Col-Treg) cells, and clinical and biological monitoring of arthritis were continued until day 56. (A) Graphed mean ± SEM data of arthritis severity
scores from day 24 of saline-injected mice (closed circles; n = 7) or mice injected with 3 × 106 Col-Treg cells (closed triangles; n = 6) or 1 × 106 Col-Treg
cells (open triangles; n = 6). *P < 0.05 (Mann–Whitney U test) indicates statistically significant difference in severity scores between mice injected with
Col-Treg cells vs. saline buffer. (B) Graph describing disease incidence in each group of mice. (C) Bovine collagen II–specific total immunoglobulin G
(IgG) levels in sera collected at the time the mice were killed. Values are expressed in arbitrary units (A.U) and represent the mean ± SEM. Similar results
were obtained in three independent experiments. Asterisks represent statistically significant differences in IgG levels between arthritic mice and mice
injected with saline buffer. Differences were analyzed by Mann–Whitney U test (*P < 0.05, **P < 0.005, ***P < 0.0005 with 95% confidence intervals).
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The proliferation of antigen-specific effector T cells was
monitored in the draining LN using the KJ1.26 antibody.
As shown in Figure 5, injection of 1 × 106 ova-Treg cells
significantly dampened the proliferation of effector T cells
into the DLNs, as revealed by the lower number of KJ1.26+
cells (Figure 5A) and the higher intensity of CFSE staining
(Figure 5B). Indeed, we observed a significant decrease in
the number of KJ1.26+ cells in the Tr1-treated mice com-
pared with controls (Figure 5C).
This DTH experimental model was also used to monitor
the homing properties of injected Tr1 cells. To this aim, a
higher dose of ova-Treg cells (10 × 106 per animal) was
injected into CD90.1 congenic BALB/c mice, and injected
ova-Treg cells were tracked using the CD90.2 marker.
Ova-Treg cells (CD90.2+) were found in the mononu-
clear cell fractions of the blood and the spleen (data not
shown), as well as in the DLNs (Figure 5D).
Altogether, these results suggest that one of the sup-
pressive mechanisms used by ova-Treg cells in vivo, fol-
lowing their migration into the DLNs, is to dampen the
proliferation of antigen-specific effector T cells.Discussion
Several lines of evidence indicate a link between Tr1 cells
and clinical improvement in RA patients. First, clinical re-
sponse to anti-TNF therapy has been associated with the
differentiation of a potent population of iTreg cells with
suppressive activity that is dependent on TGF-β and IL-10
[12]. Also, disease remission in RA patients is associated
with restored numbers of peripheral blood plasmacytoid
dendritic cells that are implicated in the maintenance of
tolerance through the induction of IL-10–secreting Tr1
cells [39]. In the present study, we evaluated, for the first
time to the best of our knowledge, the clinical benefit of
adoptively transferred in vitro differentiated Tr1 cells spe-
cific for a locally expressed antigen in two preclinical
models of arthritis.
A key question about the use of Treg cells in therapy is
to determine whether antigen-specific or polyclonal Treg
cells are more suppressive in various clinical settings. In
order to induce suppression, Treg cells must first be acti-
vated via TCRs by recognition of specific antigen major
histocompatibility complexes. Authors of several reports
have demonstrated that high TCR diversity appears to be
Figure 5 Antigen-specific type 1 regulatory T cells dampen the proliferation of effector T cells. BALB/c mice received injections of
carboxyfluorescein diacetate succinimidyl ester (CFSE)–labeled, ovalbumin (ova)-specific effector CD4+ cells on the day before subcutaneous immunization
with a mixture of ovalbumin and incomplete Freund’s adjuvant. At day 5, either phosphate-buffered saline (PBS) (n= 7) or 1 × 106 ova-specific type 1
regulatory T (ova-Treg) cells (n = 10) were injected intravenously. The mice received ova injections into their hind paws. Two days afterward, the
proliferation of CFSE+KJ1.26+ cells was analyzed by flow cytometry. (A) Representative staining results for KJ1.26+ effector T cells in the draining lymph
nodes (DLNs) are graphed. (B) Representative CFSE dilution due to the proliferation of effector KJ1.26+ T cells was analyzed using FlowJo software
(TreeStar, Ashland, OR, USA). Graph shows the same numbers of CD4+KJ1.26+ cells isolated from mice that received injections of saline (gray) or
ova-Treg cells (bold). (C) Graphed numbers of KJ1.26+ proliferating cells in the DLNs. (D) CD90.1 congenic BALB/c mice received injections of CFSE-labeled,
ova-specific effector CD4+ cells and 1 × 107 ova-Treg cells (n= 8) or PBS (n= 5). The numbers of ova-Treg cells (CD90.2+) in the DLNs are shown. Differences
were analyzed by Mann–Whitney U test with 95% confidence intervals.
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suppressive potential is probably due to increased num-
bers of activated Treg cells, which is underscored by the
facts that (1) wild-type CD4+CD25+ Treg cells have higher
suppressive capacity in lymphopenic mice [7] and (2) rele-
vant tissue-specific antigen must be present in the peri-
phery in order to generate fully protective Treg cells [41].
Concerning antigen-specific Tr1 cells, as clearly demon-
strated in an IBD experimental model, the antigen specifi-
city of the Tr1 cells is required for their local activation to
trigger their suppressive function, even if the antigen (ova)
is not implicated in the inflammation of the colon. In our
study, we chose a self-antigen specifically expressed in the
joint—Col II—to trigger local activation of Tr1 cells.
First, we demonstrated the feasibility of producing
mouse Col II–specific Tr1 cells using an experimental
protocol previously used for the production of ova-specific
Tr1 cells. The Tr1 cell identity of Col-Tregs was confirmed
by their cytokine secretion profile (IL-10highIL-4negIFN-γint)
and by their in vitro immunosuppressive activity, which
was dependent on IL-10 and TGF-β production [20,26]. In
contrast to thymus-derived CD4+CD25+ nTregs, Col-Tregcells upregulate FoxP3 and CD25 upon TCR activation
and do not express CD62L, underlining their iTreg phe-
notype. However, as described for nTregs [42], activated
Col-Treg cells do not express high levels of CD127. Over-
all, these mouse Col-Treg cells share similar characteristics
with the human Col-Treg cells that we previously obtained
from RA patients [22] and with ova-Treg cells derived
from Crohn’s disease patients lymphocytes [21].
The data presented herein indicate that a single Col-
Treg cell infusion leads to a significant decrease in clinical
symptoms in both acute and chronic models of arthritis as
measured by reductions in paw swelling, arthritic scores,
clinical incidence and body weight loss, as well as by re-
duction of Col II–specific antibody titers. Interestingly, the
results of a recent comparative study of antigen-specific
nTregs and iTregs implicated greater efficacy for the latter,
with a dose range similar to that which we used in our
present study [43]. In both models used, the Col-Treg cells
are detected in inflamed joints and axillary LNs following
injection. These data provide evidence that Col-Treg cells
are delivered to their site of action, (that is, in the arthritic
joints), thus leading to a decrease in local inflammation.
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searchers who conducted distribution studies of infusion
of CD4+CD25+ Treg cells in CIA, for which inhibition of
local inflammation is associated with a decrease in IgG
antibodies [6,7].
IL-10 has been described as the main mediator of Tr1
anti-inflammatory effects. Systemic and locally adminis-
tered IL-10 have previously been reported to have clear
therapeutic potency in CIA [44-50]. Interestingly, in those
studies, the therapeutic effect of IL-10 on anti–Col II anti-
bodies was associated with contradictory results that could
be explained by the dose and timing of the IL-10 treat-
ments. In our study, we found that the therapeutic effect
of Col-Treg cells injected at the onset of clinical signs was
associated with a global impact on anti–Col II IgG anti-
bodies, whereas a preferential decrease in the anti–Col II
IgG2a isotypes was monitored following earlier injection.
IL-10 is also a potent suppressor of macrophage activa-
tion, and intraarticular IL-10 secretion has been reported
to be associated with decreased proinflammatory cyto-
kines [51]. The local IL-10–mediated decrease in TNF-α
is a likely mechanism underlying the Tr1-protective effect
observed in the CAIA experimental model, in which neu-
trophils and macrophages are important inflammatory
cells and TNF-α and IL-1β secretion is pathogenic.
Extensive studies of the modes of action of Tr1 cells in
the two experimental models fall outside the scope of
our present study. However, to further investigate the
in vivo suppressive function of the Tr1 cells, and notably
their impact on the adaptive immune response, we pro-
vide evidence that ova-Treg cells significantly dampen
the proliferation of antigen-specific CD4 effector T cells
in DLNs. The antigen specificity of Tr1 cells is necessary
to control their activation; however, we cannot exclude
the possibility that the suppressive mechanism implies
bystander suppression and impedes the proliferation of
non-antigen-specific T effector cells. Although IL-10 has
been considered to be the main mediator of a Tr1 anti-
inflammatory effect for a long time, the concomitant
expression of other anti-inflammatory cytokines, such IL-
13, and immunomodulatory molecules, including GITR,
CTLA-4, CD39 and granzyme B, suggest that Col-Treg
cells display an arsenal of molecules able to suppress the
autoimmune response through different modes of action,
as previously described for nTregs and iTregs [33,52].
Indeed, in addition to suppression of effector T cells via
IL-10 and TGF-β secretion, expression of PD-1 (pro-
grammed cell death 1 cell surface protein) and CTLA-4
[53], adenosine production by CD39+ Tr1 cells [54] and
granzyme B–dependent killing of myeloid cells has pre-
viously been found to be associated with a suppressive
function of human Tr1 cells. The latter cytolytic activity on
macrophages and neutrophils, which are key inflammatory
cells in the CAIA experimental model, is an additionalmechanism underlying the therapeutic effect of Col-Tregs
in the CAIA model.
The results of the present pharmacokinetic studies of
injection of Col-Treg cells in arthritis confirm previous
observations in which ova-Treg cells were used in an IBD
model [26]. In severe combined immunodeficiency mice
reconstituted with CD4+CD45RBhigh T cells, the injected
ova-Treg cells were detected in inflamed tissue after
4 weeks, but not later. In our present study, we demon-
strate that Col-Treg cells were maintained after 1 week but
barely detectable after 7 to 10 days. These data indicate
that infusion of Col-Treg cells did not lead to uncontrolled
expansion in vivo, even in the continuous presence of their
specific antigens. This observation is crucial in the context
of further cell therapy protocols using Col-Treg cells in RA
patients because lymphoproliferation could be seen as a
major potential pitfall of such treatment. Furthermore, we
did not observe uncontrolled proliferation of injected cells
in long-term experiments in which Col-Tregs were injected
into naïve or arthritic mice, that is, under permanent anti-
gen exposure in the absence or presence of inflamed tissue.
Because of the heterogeneity of human Treg cells, there
is no consensus to date about which Treg population is op-
timally suited for their various clinical uses. One of the
major obstacles to the implementation of clinical protocols
using the various Tregs is the low frequency of Tregs in
the peripheral blood, which necessitates ex vivo multi-
plication of the cells prior to their use in vivo. The most
commonly used expansion protocol at present is based on
polyclonal stimulation using anti-CD3/anti-CD28 beads in
the presence of high doses of recombinant IL-2, which is
supplemented in some protocols with rapamycin. However,
the expansion is usually antigen-nonspecific. More appea-
ling for clinical application is the concept of expanding
antigen-specific Treg cells to control their activation. Im-
portantly we previously demonstrated the feasibility of pro-
ducing high numbers of clinical grade functional Col-Tregs
in RA patients [22]. Altogether, our results strongly sup-
port a further evaluation of the therapeutic potential of
Col-Treg cells in human disease. The use of Tr1 cells in
human models of disease is enhanced by their multiple
mechanisms of action, and their local immunosuppressive
action, in contrast to the systemic and single-target ap-
proaches used in the development of large numbers of bio-
logics for RA that are already approved or in development.
Patients with severe RA that is refractory to biologics rep-
resent a high unmet medical need, and antigen-specific
Tr1 cells could be an innovative approach to dampening
inflammation and restoring immune tolerance to joint an-
tigens in this patient population.
Conclusions
The data presented herein demonstrate the therapeutic
potential of antigen-specific Tr1 cells in two experimental
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velopment of novel therapeutic approaches in the treat-
ment of RA.
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